) The DNA Microarray Core will support the three research projects in colon, ovarian and lung cancer using two distinct platforms. The first platform will generate data pertaining to the expression of arrayed genes and the second will provide mutation data for a selected set of genes that are frequently mutated in cancer. All DNA microarray analyses will rely on microdissected tumors. A protocol has also been set up for expression analysis of tumor cells obtained by laser capture microdissection. It is expected that expression analysis will be undertaken for approximately 1,200 tumors from the three component projects. To this effect, a DNA microarray facility has been set up as part of the core using robotics for clone handling and for manufacturing of DNA arrays. The facility also includes a hybridization station and currently a CCD based scanner which will be upgraded in the coming year to a laser based scanner. Access to clones for arraying is provided by the Michigan Microarray Network, funded by the University of Michigan Medical Center. For the subset of genes for which proteins have been identified as part of the Proteomics Core activities, it is expected that data for expression at the RNA level will be integrated with data for expression and the protein level. We also propose to utilize the Affymetrix mutation chip to analyze colon, lung and ovarian tumors for point mutations in specific genes. In its current form the mutation chip is offered for the analysis of p53 mutations. However, it is envisaged that a more comprehensive chip will be developed for common mutations in cancer that will include K-ras as well as other genes. The DNA Microarray Core will also take advantage of work done by the applicant group through other funding, for the development of genomic microarrays that will allow identification of genomic alterations in tumors including amplification and methylation changes. The core will have access to these chips during the proposed funding period for their application to colon, ovarian and lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA084953-04
Application #
6587847
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-04-26
Project End
2003-03-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Silvers, Amy L; Lin, Lin; Bass, Adam J et al. (2010) Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res 16:2009-21
Guo, Nancy L; Wan, Ying-Wooi; Tosun, Kursad et al. (2008) Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14:8213-20
Ding, Li; Getz, Gad; Wheeler, David A et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-75
Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma; Shedden, Kerby; Taylor, Jeremy M G et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14:822-7
Wu, Rong; Hendrix-Lucas, Neali; Kuick, Rork et al. (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11:321-33
Hong, Su-Hyung; Misek, David E; Wang, Hong et al. (2006) Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. Biomark Insights 1:175-183
Hendrix, Neali D; Wu, Rong; Kuick, Rork et al. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66:1354-62
Levin, Albert M; Ghosh, Debashis; Cho, Kathleen R et al. (2005) A model-based scan statistic for identifying extreme chromosomal regions of gene expression in human tumors. Bioinformatics 21:2867-74
Shedden, Kerby A; Kshirsagar, Malti P; Schwartz, Donald R et al. (2005) Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 11:2123-31
Hinoi, Takao; Gesina, Galina; Akyol, Aytekin et al. (2005) CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology 128:946-61

Showing the most recent 10 out of 23 publications